PT-141 vs Tesamorelin
A comprehensive, data-driven comparison of PT-141 (Bremelanotide) and Tesamorelin (Egrifta). Compare efficacy, side effects, costs, FDA approval status, and clinical evidence to make an informed decision.
Side-by-Side Comparison
| Property | PT-141 Bremelanotide, Vyleesi | Tesamorelin Egrifta, TH9507 |
|---|---|---|
| FDA Status | FDA Approved | FDA Approved |
| Category | Sexual Health | Growth Hormone |
| Primary Use | Hypoactive sexual desire disorder (HSDD) in women | HIV-associated lipodystrophy |
| Weight Loss % | N/A | N/A |
| Monthly Cost | $800 - $1,200/mo | $200 - $1,500/mo |
| Administration | Subcutaneous injection | Subcutaneous injection |
| Typical Dose | 1.75mg as needed, at least 45 min before activity | 2mg daily |
| Frequency | As needed | Daily |
| Mechanism | Melanocortin receptor agonist that activates central nervous system pathways involved in sexual arousal | Synthetic GHRH analog that reduces visceral adipose tissue by stimulating growth hormone production |
| Common Side Effects |
|
|
| Serious Side Effects |
|
|
| Evidence Quality | High | High |
| Clinical Trial Phase | Approved | Approved |
Key Differences
- 1Tesamorelin is generally more affordable ($200 - $1,500/mo) compared to PT-141 ($800 - $1,200/mo).
- 2PT-141 is dosed as needed, while Tesamorelin is daily.
- 3They belong to different categories: PT-141 (Sexual Health) vs Tesamorelin (Growth Hormone).
Which Is Better For...
Tesamorelin
More budget-friendly option with lower monthly costs
PT-141
More convenient dosing schedule (as needed)
Cost Comparison
| Peptide | Monthly Cost Range | FDA Status | Manufacturer |
|---|---|---|---|
| PT-141 | $800 - $1,200/mo | FDA Approved | Cosette Pharmaceuticals (Covis Pharma) |
| Tesamorelin | $200 - $1,500/mo | FDA Approved | Theratechnologies |
Prices are estimated monthly costs and may vary based on pharmacy, insurance coverage, and manufacturer assistance programs. Costs for non-FDA-approved peptides reflect research compound pricing.
Frequently Asked Questions
PT-141 works via Melanocortin receptor agonist that activates central nervous system pathways involved in sexual. Tesamorelin works via Synthetic GHRH analog that reduces visceral adipose tissue by stimulating growth hormone. They differ in FDA approval status, efficacy data, and cost.
PT-141 typically costs $800 - $1,200/mo, while Tesamorelin costs $200 - $1,500/mo. Prices may vary by pharmacy, insurance coverage, and manufacturer programs.
PT-141 is FDA-approved. Tesamorelin is FDA-approved. FDA approval indicates the treatment has met rigorous safety and efficacy standards.
Common side effects of PT-141 include Nausea, Flushing, Injection site reactions. Common side effects of Tesamorelin include Injection site reactions, Arthralgia, Peripheral edema. Always consult a healthcare provider about potential side effects.
Switching between peptide therapies should only be done under the guidance of a qualified healthcare provider. They can evaluate your medical history, current response, and determine the safest transition protocol.
Learn More
PT-141 (Bremelanotide) is an FDA-approved peptide medication marketed as Vyleesi for treating hypoactive sexual desire disorder (HSDD) in premenopausal women. Unlike PDE5 inhibitors like Viagra, PT-14...
View Full PT-141 GuideTesamorelin is an FDA-approved synthetic growth hormone releasing hormone analog specifically indicated for reducing excess abdominal fat in HIV-infected patients with lipodystrophy. A new weekly reco...
View Full Tesamorelin GuideOther Popular Comparisons
Medical Disclaimer
The information provided on this page is for educational and informational purposes only and does not constitute medical advice. This comparison between PT-141 and Tesamorelin should not be used as a substitute for professional medical guidance. Always consult a qualified healthcare provider before starting, stopping, or modifying any peptide therapy. Clinical data cited may be from ongoing trials and is subject to change. Individual results may vary significantly. PeptideVS does not endorse, recommend, or promote the use of any specific peptide for medical treatment.